ADMA Biologics (ADMA) AI Stock Analysis

• Market Cap: $3.49B
• Dividend Yield: N/A
• Average Volume (3M): 3.26M
• Price to Earnings (P/E): 18.1
• Beta (1Y): 0.94
• Revenue Growth: 27.62%
• EPS Growth: 202.89%
• Country: US
• Employees: 685
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 238,630,720
• 10 Day Avg. Volume: 3,406,507
• 30 Day Avg. Volume: 3,260,260
• PEG Ratio: -0.03
• Price to Book (P/B): 11.45
• Price to Sales (P/S): 9.37
• P/FCF Ratio: 36.31
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $32.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 78 Outperform
• Price Target: $21.00 ▲(42.66% Upside)

ADMA Biologics scores well due to its strong financial performance and positive earnings call, which highlight robust revenue growth and strategic initiatives for future expansion. The technical analysis suggests bullish momentum, though caution is advised due to overbought signals. Valuation is reasonable, supporting the overall positive outlook.

Positive Factors

Revenue Growth

ADMA's consistent revenue growth indicates strong market demand and effective product adoption, supporting long-term financial health.

Yield Enhancement

The yield enhancement process is expected to significantly expand gross margins, enhancing profitability and competitive positioning.

Debt Refinancing

Refinancing reduces financial costs and increases liquidity, providing ADMA with greater flexibility for strategic investments and growth.

Negative Factors

Free Cash Flow Decline

A decline in free cash flow growth can limit ADMA's ability to reinvest in its business, potentially impacting future expansion and innovation.

Reimbursement Challenges

Reimbursement hurdles could slow ASCENIV's market penetration, affecting revenue growth and necessitating increased resources for payer negotiations.

Conservative Revenue Guidance

Conservative revenue guidance may indicate potential challenges in realizing expected benefits from new processes, affecting investor confidence.

ADMA Biologics Business Overview & Revenue Model

Company Description

ADMA Biologics (ADMA) is a biopharmaceutical company focused on the development and commercialization of specialty plasma-derived biologics. The company operates primarily in the healthcare sector, emphasizing the manufacture of immunoglobulins and related products that are essential for treating immune deficiencies and other serious medical conditions. ADMA's core products include Intravenous Immunoglobulin (IVIG) and subcutaneous immunoglobulin formulations, which are designed to improve the quality of life for patients with compromised immune systems.

How the Company Makes Money

ADMA generates revenue primarily through the sales of its immunoglobulin products, including its flagship product, ASCENIV, which is marketed for the treatment of primary immunodeficiency diseases. The company also derives income from the sale of other plasma-derived therapies, which are distributed through specialty pharmacies and healthcare providers. Key revenue streams include direct product sales, partnerships with healthcare facilities, and contracts with distributors. Additionally, ADMA has engaged in collaborations and strategic partnerships that enhance its market reach and provide financial support for its product development initiatives, contributing to its overall earnings.

ADMA Biologics Financial Statement Overview

Summary

ADMA Biologics demonstrates strong financial performance with robust revenue growth and profitability improvements. The company maintains a solid balance sheet with low leverage and high return on equity. However, there are concerns regarding the recent decline in free cash flow growth, which slightly tempers the overall financial performance score.

Income Statement

ADMA Biologics has shown strong revenue growth with a TTM revenue increase of 3.03% and a significant improvement in profitability. The gross profit margin improved to 53%, and the net profit margin is robust at 44.06%. The EBIT and EBITDA margins are also strong at 32.73% and 34.40%, respectively, indicating efficient operations. These metrics reflect a positive trajectory in revenue and profitability, although the growth rate has slightly decelerated compared to previous years.

Balance Sheet

The balance sheet of ADMA Biologics shows a healthy debt-to-equity ratio of 0.21, indicating low leverage and financial stability. The return on equity is impressive at 61.78%, reflecting strong profitability relative to shareholder equity. The equity ratio stands at 75.80%, suggesting a solid capital structure. However, the company has experienced fluctuations in debt levels over the years, which could pose potential risks if not managed carefully.

Cash Flow

The cash flow statement reveals a decline in free cash flow growth by 38.37% in the TTM period, which is a concern. However, the operating cash flow to net income ratio is slightly above 1, indicating that operating cash flows are covering net income. The free cash flow to net income ratio is strong at 86.16%, suggesting efficient cash generation relative to net income. Despite the recent decline in free cash flow, the overall cash flow position remains relatively stable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	488.56M	426.45M	258.21M	154.08M	80.94M	42.22M
Gross Profit	267.28M	219.55M	88.94M	35.27M	1.17M	-19.07M
EBITDA	172.13M	147.69M	5.12M	-39.51M	-53.09M	-59.82M
Net Income	209.45M	197.67M	-28.24M	-65.90M	-71.65M	-75.75M
Balance Sheet
Total Assets	568.69M	488.68M	329.18M	348.46M	276.25M	207.67M
Cash, Cash Equivalents and Short-Term Investments	61.38M	103.15M	51.35M	86.52M	51.09M	55.92M
Total Debt	83.12M	82.12M	141.42M	154.44M	102.92M	97.67M
Total Liabilities	137.50M	139.66M	193.98M	196.49M	135.08M	119.42M
Stockholders Equity	431.19M	349.02M	135.21M	151.97M	141.17M	88.25M
Cash Flow
Free Cash Flow	40.73M	110.10M	3.82M	-73.42M	-125.88M	-114.73M
Operating Cash Flow	64.97M	118.67M	8.80M	-59.51M	-112.37M	-102.00M
Investing Cash Flow	-24.36M	-8.57M	-4.98M	-13.91M	-13.51M	-12.72M
Financing Cash Flow	-65.93M	-58.30M	-38.99M	108.85M	121.05M	143.90M

ADMA Biologics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMA, the sentiment is Positive. The current price of 14.72 is below the 20-day moving average (MA) of 16.22, below the 50-day MA of 15.50, and below the 200-day MA of 17.89, indicating a bullish trend. The MACD of 0.93 indicates Negative momentum. The RSI at 73.69 is Negative, neither overbought nor oversold. The STOCH value of 94.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADMA.

ADMA Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	78 Outperform	$3.49B	18.10	63.17%	―	27.62%	202.89%
PTGX	70 Neutral	$5.63B	142.20	7.80%	―	-35.39%	-72.97%
ARWR	57 Neutral	$7.84B	―	-0.50%	―	23258.15%	99.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMVT	45 Neutral	$4.15B	―	-95.93%	―	―	-27.70%
MLTX	41 Neutral	$984.96M	―	-54.17%	―	―	-157.74%
ACLX	41 Neutral	$4.24B	―	-47.18%	―	-76.96%	-425.41%

ADMA Biologics Corporate Events

ADMA Biologics Inc. Reports Strong Q3 Earnings Call

ADMA Biologics Inc. Reports Strong Q3 Performance Amid Strategic Initiatives

ADMA Biologics Reports Strong Q3 2025 Financial Results

ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company specializing in the manufacturing, marketing, and development of specialty biologics, particularly plasma-derived products for immunodeficient patients. The company has announced its third-quarter 2025 financial results, highlighting a 12% year-over-year increase in total revenue to $134.2 million and a 1% increase in GAAP net income to $36.4 million. Adjusted EBITDA saw a significant rise of 29% to $58.7 million, reflecting strong operational performance.